Evidence map›Paper›PMID 26641662›Full record

ArticlePloS one2015

Surface Modification of Biodegradable Polymers towards Better Biocompatibility and Lower Thrombogenicity.

Andreas Rudolph, Michael Teske, Sabine Illner, Volker Kiefel, Katrin Sternberg, Niels Grabow, Andreas Wree, Marina Hovakimyan

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. PreclinicalFrontiers in bioengineering and biotechnology · 2023
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Andreas RudolphInstitute for Biomedical Engineering, Rostock University Medical Center, Friedrich-Barnewitz-Strasse 4, D-18119, Rostock, Germany.
Michael TeskeInstitute for Biomedical Engineering, Rostock University Medical Center, Friedrich-Barnewitz-Strasse 4, D-18119, Rostock, Germany.
Sabine IllnerInstitute for Biomedical Engineering, Rostock University Medical Center, Friedrich-Barnewitz-Strasse 4, D-18119, Rostock, Germany.
Volker KiefelDepartment of Transfusion Medicine, Rostock University Medical Center, Ernst-Heydemann-Strasse 6, D-18057, Rostock, Germany.
Katrin SternbergInstitute for Biomedical Engineering, Rostock University Medical Center, Friedrich-Barnewitz-Strasse 4, D-18119, Rostock, Germany.
Niels GrabowInstitute for Biomedical Engineering, Rostock University Medical Center, Friedrich-Barnewitz-Strasse 4, D-18119, Rostock, Germany.
Andreas WreeInstitute of Anatomy, Rostock University Medical Center, Gertrudenstrasse 9, D-18057, Rostock, Germany.
Marina HovakimyanInstitute for Biomedical Engineering, Rostock University Medical Center, Friedrich-Barnewitz-Strasse 4, D-18119, Rostock, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDrug-eluting stents (DES) based on permanent polymeric coating matrices have been introduced to overcome the in stent restenosis associated with bare metal stents (BMS). A further step was the development of DES with biodegradable polymeric coatings to address the risk of thrombosis associated with first-generation DES. In this study we evaluate the biocompatibility of biodegradable polymer materials for their potential use as coating matrices for DES or as materials for fully bioabsorbable vascular stents. MATERIALS AND

methodsFive different polymers, poly(L-lactide) PLLA, poly(D,L-lactide) PDLLA, poly(L-lactide-co-glycolide) P(LLA-co-GA), poly(D,L-lactide-co-glycolide) P(DLLA-co-GA) and poly(L-lactide-co-ε-caprolactone), P(LLA-co-CL) were examined in vitro without and with surface modification. The surface modification of polymers was performed by means of wet-chemical (NaOH and ethylenediamine (EDA)) and plasma-chemical (O2 and NH3) processes. The biocompatibility studies were performed on three different cell types: immortalized mouse fibroblasts (cell line L929), human coronary artery endothelial cells (HCAEC) and human umbilical vein endothelial cells (HUVEC). The biocompatibility was examined quantitatively using in vitro cytotoxicity assay. Cells were investigated immunocytochemically for expression of specific markers, and morphology was visualized using confocal laser scanning (CLSM) and scanning electron (SEM) microscopy. Additionally, polymer surfaces were examined for their thrombogenicity using an established hemocompatibility test.

resultsBoth endothelial cell types exhibited poor viability and adhesion on all five unmodified polymer surfaces. The biocompatibility of the polymers could be influenced positively by surface modifications. In particular, a reproducible effect was observed for NH3-plasma treatment, which enhanced the cell viability, adhesion and morphology on all five polymeric surfaces.

conclusionSurface modification of polymers can provide a useful approach to enhance their biocompatibility. For clinical application, attempts should be made to stabilize the plasma modification and use it for coupling of biomolecules to accelerate the re-endothelialization of stent surfaces in vivo.

Indexed as

AnimalsBiocompatible MaterialsCell LineCoronary VesselsDrug-Eluting StentsFibroblastsHumansHuman Umbilical Vein Endothelial CellsMicePolymersStentsSurface PropertiesThrombosisBiocompatible MaterialsPolymers

Identifiers

PMID26641662
PMCPMC4671536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.